Metabolically Unhealthy Phenotype: A Key Factor in Determining "Pediatric" Frailty

Valeria Calcaterra1,2, Hellas Cena3,4, Annamaria Ruggieri5

  • 1Pediatric and Adolescent Unit, Department of Internal Medicine, University of Pavia, 27100 Pavia, Italy.

Pediatric Reports
|July 21, 2021
PubMed

Insights

Metabolic syndrome (MS) is linked to frailty (FI) in children with disabilities and obesity, similar to elderly individuals. Addressing MS is crucial for pediatric frailty care.

Area of Science:

  • Pediatrics
  • Geriatrics
  • Metabolic Health

Background:

  • Frailty (FI) and metabolic syndrome (MS) are linked to poor health outcomes in adults.
  • Understanding the connection between FI and MS in pediatric populations is essential.

Purpose of the Study:

  • To investigate the prevalence of a metabolically unhealthy phenotype (MUP) in malnourished disabled children, children with obesity, and normal-weight children.
  • To compare MUP prevalence in these pediatric groups with elderly individuals at risk of FI.
  • To identify potential similarities underlying the risk of FI in specific pediatric groups.

Main Methods:

  • Studied 50 malnourished disabled children, 50 children with obesity, 50 normal-weight children, and 21 elderly patients (>75 years).
  • Defined MUP by the presence of hypertension, hyperglycemia/diabetes, hypercholesterolemia, or hypertriglyceridemia.
  • Utilized body mass index (BMI) standard deviation scores (SDS) for pediatric weight classification.

Main Results:

  • Disabled children and children with obesity showed a significantly higher prevalence and risk of MUP compared to normal-weight children.
  • MUP prevalence in disabled children was comparable to elderly patients at risk of FI.
  • MUP was less prevalent in children with obesity and normal-weight children compared to the elderly group.

Conclusions:

  • Metabolic syndrome (MS) may significantly contribute to pediatric frailty (FI).
  • Malnutrition and the extremes of aging appear to be key factors in developing frailty.
  • A multidisciplinary approach is recommended for managing pediatric frailty.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
45
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
787
Overview of Protein Metabolism01:21

Overview of Protein Metabolism

Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
2.5K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
34
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
387
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
3.3K